XML 63 R46.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Other (Income)/Deductions - Net (Footnotes) (Detail) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended |
--- | --- | --- | ---
Oct. 01, 2017 | Oct. 02, 2016 | Oct. 01, 2017 | Oct. 02, 2016 | Jun. 30, 2017
Loss Contingencies [Line Items] |  |  |  |  |  |
Royalty revenue | [1] | $ 140 | $ 233 | $ 331 | $ 695 |
Gain on sale of investments |  | 66 |  | 183 |  |
Gain on sale of property |  |  |  | 52 |  |
Intangible asset impairment charges |  |  | $ 126 |  | 767 |
Income from contract resolution |  | 62 |  | 62 | 116 |
Payments for merger termination costs |  |  |  |  | $ 150 |
Laboratorio Teuto Brasilero [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Equity method investment, ownership percentage |  |  | 40.00% |  | 40.00% | 40.00%
Loss on disposal of equity method investment |  |  |  | 30 |  |
Equity method investment, impairment |  |  |  |  | $ 50 |
Hisun Pfizer Pharmaceuticals Co. Ltd [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Equity method investment, ownership percentage |  |  | 49.00% |  | 49.00% |
Equity method investment, impairment |  |  |  |  | $ 211 |
Xtandi [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Royalty revenue |  | 73 |  | 160 |  |
Distribution Rights [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Gain on disposition of intangible assets |  | 71 |  | 141 | 49 |
Developed Technology Rights [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Intangible asset impairment charges |  |  |  |  | 331 |
Collaborative Arrangement, Co-promotion [Member] | Enbrel [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Decrease in royalty revenue |  | 139 |  | $ 414 |  |
Royalty period |  |  |  | 36 months |  |
Pending Litigation [Member] | Celebrex [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Litigation settlement expense |  | 94 |  | $ 94 |  |
Pending Litigation [Member] | Celebrex and Bextra [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Amount awarded to other party |  |  |  |  | 486 |
In Process Research and Development [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Intangible asset impairment charges |  |  |  |  | 265 |
Other In Process Research and Development [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Intangible asset impairment charges |  |  |  |  | 74 |
Hospira [Member] | Other In Process Research and Development [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Intangible asset impairment charges |  |  |  |  | 45 |
InnoPharma [Member] | In Process Research and Development [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Intangible asset impairment charges |  |  | $ 97 |  | 97 |
King [Member] | Other In Process Research and Development [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Intangible asset impairment charges |  |  | 29 |  | 29 |
Operating Segments [Member] | EH [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Intangible asset impairment charges |  |  | 97 |  | 738 |
Operating Segments [Member] | EH [Member] | Hospira [Member] | Developed Technology Rights [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Intangible asset impairment charges |  | 127 |  | 127 |  |
Operating Segments [Member] | IH [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Intangible asset impairment charges |  |  | $ 29 |  | $ 29 |
Operating Segments [Member] | IH [Member] | ViiV Healthcare Limited [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Dividend income |  | 54 |  | 211 |  |
Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Ownership percentage |  |  |  |  |  | 60.00%
Patent Matter [Member] | Pending Litigation [Member] |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |
Litigation settlement expense |  | $ 79 |  | $ 79 |  |
[1] | Royalty-related income decreased in the third quarter and first nine months of 2017, primarily due to lower royalty income for Enbrel of $139 million and $414 million, respectively, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of $73 million and $160 million, respectively.

X
- Definition Decrease in Royalty Revenue + References No definition available. + Details
Name: | pfe_DecreaseinRoyaltyRevenue
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Other Nonoperating Income, Miscellaneous + References No definition available. + Details
Name: | pfe_OtherNonoperatingIncomeMiscellaneous
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments for Merger Termination Costs + References No definition available. + Details
Name: | pfe_PaymentsforMergerTerminationCosts
Namespace Prefix: | pfe_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty Revenue, Term + References No definition available. + Details
Name: | pfe_RoyaltyRevenueTerm
Namespace Prefix: | pfe_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 35 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=99375318&loc=d3e32787-111569 + Details
Name: | us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of gain (loss) on sale or disposal of an equity method investment. + References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of gain (loss) on sale or disposal of intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7,9) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 + Details
Name: | us-gaap_GainLossOnDispositionOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 + Details
Name: | us-gaap_GainLossOnSaleOfPropertyPlantEquipment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale. + References No definition available. + Details
Name: | us-gaap_GainOnSaleOfInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of dividend income on nonoperating securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_InvestmentIncomeDividend
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount awarded to other party in judgment or settlement of litigation. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The parent entity's interest in net assets of the subsidiary, expressed as a percentage. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByParent
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_RoyaltyRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_XtandiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementCopromotionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_EnbrelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_CelebrexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=pfe_CelebrexandBextraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_OtherInProcessResearchandDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=pfe_InnoPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=pfe_KingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_EssentialHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_InnovativeHealthSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=pfe_LaboratorioTeutoBrasileroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentMatterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |